Graff Jeremy R. 4/A

What Happened
Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, was granted 133,333 restricted stock units (RSUs) on January 28, 2026. The grant was reported as an award (code A) with an acquisition price of $0.00 (no cash paid at grant). The award is made under Allarity’s Amended and Restated 2021 Equity Incentive Plan.

Key Details

• Transaction date: 2026-01-28; Form 4 amendment filed 2026-04-30 (amended/late filing).
• Award: 133,333 RSUs at $0.00 per share (total acquisition value reported $0).
• Vesting: RSUs vest in equal one‑third installments on the 1st, 2nd and 3rd anniversaries of the grant, subject to continued relationship with the company (per footnote).
• Shares owned after transaction: not disclosed in this filing.
• Filing status: This is an amended Form 4 filed well after the transaction date; investors relying on timeliness should note the delayed disclosure.

Context
RSUs are compensation awards that convert to shares only as they vest; they are not an immediate market purchase or sale and require no cash outlay at grant. Such grants are typically part of executive compensation and do not, by themselves, indicate an insider buying or selling shares on the open market.